Prostate Cancer: Staging (MP11): Moderated Poster 11: Friday, September 10, 2021
MP11-10 RE-REFERRAL RATES IN THE MEDIUM TERM IN PATIENTS WITH A NON-SUSPICIOUS MPMRI WITHIN THE RAPID PATHWAY
INTRODUCTION AND OBJECTIVE:
Our ‘one-stop’ Rapid Access Prostate Imaging and Diagnosis (RAPID) pathway across five hospitals in our region streamlined our one-stop mpMRI and if required, transperineal prostate biopsies. We report on the re-referral rates of men who had undergone previous investigation on the RAPID pathway.
Data from consecutive patients on the RAPID pathway (April/2017 to December/2020) was entered into the online RAPID registry. A transperineal targeted and systematic prostate biopsy (TP-Bx) was offered on the same day if the mpMRI score was 4 or 5. A score of 3 required a PSA density ≥ 0.12. The re-referral assessment was checked based on computer assistance.
2869 patients with mean age 66 [IQR 59-72] and mean PSA 7.5 (5.8-11.3) were referred for prostate cancer investigation. In total, 49% [1406/2869] were discharged without a suspicion of cancer. 3% (37/1196) were rereferred by their GP due to ongoing concern for prostate cancer. Mean age was 67 (46-80) and mean PSA 9.5 (1.4-19.5). From those, 13 (35%) required biopsy in addition to MRI. Four (10%) had a histological diagnosis of prostate cancer of Gleason 3+4.
RAPID is a safe pathway in the medium term when discharging men without biopsy following a non-suspicious mpMRI. After 3 years of follow-up, the mpMRI diagnostic pathway has a low re-referral rate and even on the rereferral group, 65% still did not meet criteria for a biopsy.
Source of Funding:
None© 2021 by American Urological Association Education and Research, Inc.